Search
forLearn
5 / 801 resultslearn multipeptides
learn Pea peptides
learn sh-Polypeptide-7
learn oligopeptide-71
Research
5 / 840 results
research The Significance of Scalp Involvement in Pemphigus: A Literature Review
Scalp involvement is common in pemphigus and can lead to hair loss, with the severity of scalp lesions linked to overall disease severity.
research Pemphigus vulgaris in only one of two monozygotic twins
Genetic factors alone might not cause pemphigus vulgaris; other factors like birth complications and puberty may trigger it.
research Regulatory T cells in autoimmune skin diseases
Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.
research DEVELOPMENT OF A DESMOCOLLIN-3 ACTIVE MOUSE MODEL RECAPITULATING HUMAN ATYPICAL PEMPHIGUS
Anti-Desmocollin 3 antibodies can cause atypical pemphigus symptoms.
research Autoimmune skin disease pathogenesis: a chronological immune cascade and multi-hit model
Autoimmune skin diseases result from genetic and environmental factors disrupting immune checkpoints.
Community Join
5 / 1000+ resultscommunity Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community New Hair Loss Cure: AMP-303 Is Back. It’s what PP405 should have been.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Does anyone know the chemical formula for pelage pp405?
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.